New COPD use case, Nucala expands GSK’s respiratory bet

GSK’s Nucala, long used in severe asthma, has just been approved in Canada as an add-on maintenance treatment for certain COPD patients with eosinophilic inflammation, sharpening the drug’s role in the British group’s respiratory portfolio.

Edited by ad hoc news New Releases & Launches Desk. Reviewed before publication on 06/16/2026 at 1:40 PM ET. Details in the imprint.

GSK’s biologic Nucala is stepping beyond severe asthma, with Health Canada approving mepolizumab as an add-on maintenance treatment for adults with chronic obstructive pulmonary disease (COPD) who have eosinophilic inflammation despite standard inhaled therapy, adding a fresh launch twist to the established respiratory medicine.

What the new Nucala COPD indication in Canada actually offers

Nucala (mepolizumab) is a monoclonal antibody that targets interleukin-5 (IL-5), a key cytokine driving the production and survival of eosinophils, and has been marketed for years as an add-on therapy in severe eosinophilic asthma, chronic rhinosinusitis with nasal polyps and eosinophilic granulomatosis with polyangiitis. The newly granted Canadian indication extends its use to adult COPD patients whose disease remains poorly controlled on optimized inhaled triple therapy and who show elevated blood eosinophil counts and frequent exacerbations, essentially mirroring the eosinophilic phenotype Nucala already addresses in asthma. GSK’s Canadian product information specifies that Nucala is administered as a 100 mg subcutaneous injection every four weeks, either by a healthcare professional or via a prefilled autoinjector or syringe, depending on local practice and patient suitability, keeping the COPD dosing schedule aligned with existing asthma use. The company frames the drug in COPD as an add-on to background bronchodilator and inhaled corticosteroid regimens rather than a replacement, aiming to reduce exacerbation frequency rather than improve lung function alone, and emphasizes that appropriate patient selection based on eosinophil levels and clinical history is critical for benefit. In pre-approval trials in eosinophilic COPD, mepolizumab reduced moderate to severe exacerbation rates compared with placebo when added to maximal inhaled therapy in patients with elevated blood eosinophils, while safety findings were broadly consistent with its established profile in severe asthma.

The Canadian regulatory move underscores GSK’s strategy of extracting more value from Nucala by systematically expanding its label into eosinophil-driven disease segments that share similar underlying biology, while using post-marketing and real-world evidence to refine positioning. According to health policy reporting that flagged the approval, Health Canada has authorized mepolizumab as an add-on maintenance treatment in adult COPD patients with eosinophilic inflammation who continue to experience exacerbations despite optimized inhaled treatment, extending Nucala’s footprint in a disease area with limited biologic options. One recent industry analysis highlighted the Health Canada decision as an example of regulators relying on targeted clinical data and real-world evidence for respiratory biologics. While Nucala is already available in the United States for severe eosinophilic asthma and other indications, the COPD approval currently applies to the Canadian market, where pricing and reimbursement will be shaped by federal and provincial negotiators.

For Canadian patients, the practical impact is likely to be most visible among those with frequent exacerbations and high eosinophil counts who cycle repeatedly through hospital and emergency department visits despite triple inhaler therapy. Nucala’s subcutaneous, once-every-four-weeks dosing may appeal to clinicians managing complex COPD cases who are familiar with biologic administration from asthma clinics, yet uptake will depend heavily on reimbursement and clear guidance on biomarker cut-offs. GSK has previously positioned Nucala as the first-in-class anti-IL-5 therapy for severe eosinophilic asthma, and it is now using that heritage to frame the COPD indication as a logical extension into another eosinophil-driven airway disease, rather than a repositioning of the drug. The company’s official product documentation stresses that Nucala is not intended for relief of acute bronchospasm or status asthmaticus, a caveat that equally applies in COPD where short-acting bronchodilators remain the rescue mainstay. As in other indications, common adverse reactions include headache, injection site reactions and back pain, with hypersensitivity reactions also listed, so Canadian prescribers will need to balance exacerbation reduction potential against these known risks on a patient-by-patient basis. GSK’s Canadian labeling further notes that Nucala can be self-administered in some indications after appropriate training, but COPD patients with significant disability may continue to receive injections in clinical settings.

Strategically, GSK is leaning on Nucala as one pillar of a broader respiratory and immunology franchise that also includes newer biologics and inhaled therapies, using each incremental indication to support the brand’s longevity as competitors arrive. In company materials summarizing Nucala’s development history, GSK stresses that mepolizumab was the first anti-IL-5 monoclonal antibody approved for severe eosinophilic asthma and that its mechanism of selectively blocking IL-5 reduces blood eosinophil levels, aligning with the eosinophilic endotype that has emerged as a distinct subgroup across airway diseases. GSK’s official Nucala product page details its indications, dosing and safety profile across asthma and other eosinophilic diseases, and the Canadian COPD label sits on top of that foundation rather than rewriting it. From a portfolio perspective, adding COPD to Nucala’s use cases may help GSK offset pricing and competitive pressures in asthma, while also showing regulators and payers that the company can generate targeted evidence in biomarker-defined subgroups where unmet need is still significant.

Within GSK’s pipeline and marketed lineup, Nucala functions as a mid-to-late lifecycle asset that still has room for geographic and indication expansion, especially in markets where biologic penetration in respiratory disease remains comparatively low. Analysts often group Nucala with other key specialty medicines when modeling GSK’s revenues, and any incremental use in COPD could provide modest support to the broader respiratory franchise without meaningfully changing the group’s overall earnings profile in the near term. In recent quarterly reports, GSK has highlighted respiratory and immunology as a core growth area within its specialty medicines segment, with Nucala named among the contributors alongside newer launches. Shares of GSK (GB0009252882) trade on the London Stock Exchange in pounds sterling and as ADRs on the NYSE in US dollars, giving international investors exposure to the company’s respiratory portfolio including Nucala.

Nucala in brief: key facts on GSK’s biologic

• Product: Nucala (mepolizumab)
• Manufacturer: GSK plc
• Category: New Release/Launch - respiratory biologic indication
• Launch date: COPD indication recently approved in Canada; Nucala originally launched earlier for severe eosinophilic asthma
• MSRP / Price: Not publicly listed; pricing in Canada will depend on negotiations and reimbursement decisions
• Availability: Prescription biologic, available in Canada for approved indications via hospitals and specialist clinics; also marketed in the US and other markets for asthma and eosinophilic diseases
• Target audience: Adults with eosinophilic COPD who have frequent exacerbations despite optimized inhaled therapy, and other patients with approved eosinophilic indications
• Key differentiator / USP: First anti-IL-5 monoclonal antibody to extend from severe eosinophilic asthma into an eosinophilic COPD indication in Canada, with fixed 100 mg subcutaneous dosing every four weeks

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.